EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics […]

read more

EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate

Patent Further Strengthens EyeGate’s Global IP Protection for Lead Product Candidate, EGP-437 WALTHAM, Mass., January 23, 2017 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or […]

read more

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Jan. 09, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing […]

read more

EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients

Company Plans to Initiate Randomized, Double-masked, Placebo-Controlled Study in First Half of 2017 WALTHAM, Mass., Dec. 05, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or […]

read more

FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting

WALTHAM, Mass., November 17, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and […]

read more

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 02, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]

read more

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

WALTHAM, Mass., Sept. 21, 2016 — EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]

read more

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

Funds to Advance Pre-clinical Development of CMHA-S Ocular Bandage Film WALTHAM, Mass., September 13, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), […]

read more

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Sept. 12, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]

read more

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 06, 2016 — EYEG (Nasdaq: EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for […]

read more